PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-35.79%
Both companies show declining cash positions (-35.79% vs AXSM's -10.30%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-35.79%
Cash + STI yoy ≥ 1.5x AXSM's -10.30%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.27%
Higher Other Current Assets Growth compared to AXSM's zero value, indicating worse performance.
-32.53%
≥ 1.5x AXSM's -10.33%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-2.15%
Below half AXSM's 12.72%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.04%
Less than half of AXSM's 2.65%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-1.56%
Below half of AXSM's 4.45%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-28.33%
≥ 1.5x AXSM's -10.31%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-12.11%
Less than half of AXSM's 11.41%. David Dodd sees a more disciplined AP approach or lower volume.
-29.66%
Less than half of AXSM's 75.55%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
6.29%
Below half of AXSM's -20.00%. Michael Burry suspects a big gap in pre-sales traction.
100.00%
Higher Other Current Liabilities Growth compared to AXSM's zero value, indicating worse performance.
-11.86%
Less than half of AXSM's 6.55%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Non-Current Liabilities Growth compared to AXSM's zero value, indicating worse performance.
-7.08%
50-75% of AXSM's -10.32%. Bruce Berkowitz notes a smaller yoy liability buildup than competitor.
No Data
No Data available this quarter, please select a different quarter.
-11.32%
Above 1.5x AXSM's -0.44%. Michael Burry sees a potential leverage warning sign.
6.25%
Above 1.5x AXSM's 0.38%. Michael Burry suspects heavy new equity expansion or dilution.
-2.72%
Below half AXSM's -18.47%. Michael Burry suspects major net losses or high dividends vs. competitor.
100.00%
Similar yoy to AXSM's 100.00%. Walter Schloss sees parallel comprehensive income changes.
No Data
No Data available this quarter, please select a different quarter.
-46.50%
≥ 1.5x AXSM's -18.47%. David Dodd sees stronger capital base growth than competitor.
-28.33%
1.25-1.5x AXSM's -24.37%. Bruce Berkowitz checks if expansions are well-justified by ROI.
No Data
No Data available this quarter, please select a different quarter.
-8.76%
Less than half of AXSM's 0.89%. David Dodd sees less overall debt expansion vs. competitor.
40.72%
Above 1.5x AXSM's 11.41%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.